Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
相关临床试验
291
160 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1999
进行中（未招募）
156
53.6%
已完成
110
37.8%
尚未招募
4
1.4%
招募中
2
0.7%
终止
18
6.2%
撤回
1
0.3%
暂无批准数据
- Third Arc Bio closed a $52 million Series A extension led by Andreessen Horowitz, bringing total Series A funding to $217 million to expand its oncology and immunology pipeline. - The company's lead asset ARC101, a bispecific T-cell engager targeting CLDN6, is currently in Phase 1 dose-escalation studies for advanced solid tumors. - Third Arc Bio's ARCTag platform uses multispecific antibodies to localize immune modulation directly to disease sites, potentially improving therapeutic index over systemic autoimmune therapies. - Proceeds will accelerate the immunology and inflammation portfolio while advancing additional oncology programs into clinical trials.
- Galapagos NV has appointed Aaron Cox as Chief Financial Officer effective July 7, 2025, bringing over two decades of biotechnology and M&A expertise to the Belgian biotech company. - Cox previously served as CFO at Horizon Therapeutics, where he played a pivotal role in the company's $28 billion acquisition by Amgen in 2022. - The appointment positions Galapagos to leverage its $3.3 billion cash reserves for strategic acquisitions and explore value-maximizing alternatives for its cell therapy business. - Cox will lead efforts to accelerate pipeline growth through business development while managing the company's transformation with disciplined financial oversight.
• e-therapeutics has presented new preclinical data demonstrating ETX-312, their GalOmic siRNA candidate, significantly improves NAFLD Activity Score in MASH mouse models both as monotherapy and in combination with other agents. • The experimental treatment showed comparable fibrosis progression reduction to GLP-1/GIP receptor agonists and FGF-21 analogues, with statistically significant reductions in hepatic collagen staining and circulating biomarkers. • ETX-312, currently in IND-enabling studies, is being developed with potential for quarterly subcutaneous dosing, with regulatory submission planned by the end of 2025.
• AbbVie has partnered with Galapagos NV in a global alliance worth up to $406 million to discover and develop combination therapies targeting key mutations in cystic fibrosis patients. • The collaboration aims to develop oral drugs addressing F508del and G551D mutations in the CFTR protein, with plans to initiate Phase 1 clinical trials by the end of 2014. • This partnership joins other significant industry efforts to combat cystic fibrosis, including Pfizer's expanded six-year research program with the Cystic Fibrosis Foundation worth up to $58 million.
• Galapagos NV initiates HESPERIA study to monitor long-term safety and efficacy of their CAR-T therapies across multiple hematologic malignancies over a 15-year period. • The company's lead candidate GLPG5101, targeting CD19, demonstrates potential 7-day manufacturing time and is being evaluated for various B-cell malignancies including DLBCL and follicular lymphoma. • HESPERIA study aims to enroll 546 patients across European sites, tracking critical endpoints including adverse events, CAR transgene levels, and overall survival rates.
- Catalent and Galapagos NV have formed a strategic collaboration to support decentralized manufacturing of GLPG5101, an investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma. - The partnership leverages Catalent's Princeton facility to deliver fresh CAR-T cells with a median vein-to-vein time of seven days, eliminating the need for cryopreservation and bridging therapy. - This innovative manufacturing approach aims to improve patient experience by bringing production closer to cancer treatment centers across New Jersey, New York, and surrounding areas.
• Galapagos NV secured FDA IND clearance for GLPG5101, a CAR-T therapy, enabling U.S. patient recruitment for Phase II ATALANTA study in non-Hodgkin lymphoma. • The company is progressing over 15 programs, planning at least four IND-enabling studies in 2025, focusing on oncology and immunology. • Strategic collaborations with Blood Centers of America and Adaptimmune are expanding Galapagos' cell therapy manufacturing network and capabilities. • Galapagos maintains a strong cash position of EUR 3.3 billion, supporting its R&D efforts and business development opportunities in oncology and immunology.
